๐Ÿ’พ Data Updated: 2025 HTS Revision 30 โ€ข Last updated: November 24, 2025

2934.30.27.00 - Other

Details

FieldValue
Unit of Quantitykg
General Rate of Duty6.5%
Special Rate of DutyFree (A+,AU,BH,CL,CO,D, E,IL,JO,K, KR,MA,OM,P, PA,PE,S,SG)
A+ ๐Ÿ‡ฆ๐Ÿ‡ซ ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡น ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡ง๐Ÿ‡ฎ ๐Ÿ‡ฐ๐Ÿ‡ญ ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ช๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ฐ๐Ÿ‡ฎ ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ฒ๐Ÿ‡ฒ ๐Ÿ‡ณ๐Ÿ‡ต ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ผ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ธ๐Ÿ‡ง ๐Ÿ‡ธ๐Ÿ‡ด ๐Ÿ‡ธ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ฑ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡น๐Ÿ‡ป ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡ป๐Ÿ‡บ ๐Ÿ‡พ๐Ÿ‡ช ๐Ÿ‡ฟ๐Ÿ‡ฒ
AU ๐Ÿ‡ฆ๐Ÿ‡บ
BH ๐Ÿ‡ง๐Ÿ‡ญ
CL ๐Ÿ‡จ๐Ÿ‡ฑ
CO ๐Ÿ‡จ๐Ÿ‡ด
D ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡จ๐Ÿ‡ป ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ธ๐Ÿ‡ฟ ๐Ÿ‡ช๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ฆ ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ญ ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ฐ๐Ÿ‡ช ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡บ ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ณ๐Ÿ‡ฆ ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ณ๐Ÿ‡ฌ ๐Ÿ‡จ๐Ÿ‡ฌ ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ฟ๐Ÿ‡ฆ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡ฟ๐Ÿ‡ฒ
E ๐Ÿ‡ฆ๐Ÿ‡ฌ ๐Ÿ‡ฆ๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ธ ๐Ÿ‡ง๐Ÿ‡ง ๐Ÿ‡ง๐Ÿ‡ฟ ๐Ÿ‡ป๐Ÿ‡ฌ ๐Ÿ‡จ๐Ÿ‡ผ ๐Ÿ‡ฉ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ฉ ๐Ÿ‡ฌ๐Ÿ‡พ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ฏ๐Ÿ‡ฒ ๐Ÿ‡ฒ๐Ÿ‡ธ NE ๐Ÿ‡ฐ๐Ÿ‡ณ ๐Ÿ‡ฑ๐Ÿ‡จ ๐Ÿ‡ป๐Ÿ‡จ ๐Ÿ‡น๐Ÿ‡น
IL ๐Ÿ‡ฎ๐Ÿ‡ฑ
JO ๐Ÿ‡ฏ๐Ÿ‡ด
K ๐Ÿ‡ฆ๐Ÿ‡ซ ๐Ÿ‡ฆ๐Ÿ‡ฑ ๐Ÿ‡ฆ๐Ÿ‡ฉ ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ฆ๐Ÿ‡ฎ ๐Ÿ‡ฆ๐Ÿ‡ฌ ๐Ÿ‡ฆ๐Ÿ‡ท ๐Ÿ‡ฆ๐Ÿ‡ฒ ๐Ÿ‡ฆ๐Ÿ‡ผ ๐Ÿ‡ฆ๐Ÿ‡บ ๐Ÿ‡ฆ๐Ÿ‡น ๐Ÿ‡ฆ๐Ÿ‡ฟ ๐Ÿ‡ง๐Ÿ‡ธ ๐Ÿ‡ง๐Ÿ‡ญ ๐Ÿ‡ง๐Ÿ‡ฉ ๐Ÿ‡ง๐Ÿ‡ง ๐Ÿ‡ง๐Ÿ‡พ ๐Ÿ‡ง๐Ÿ‡ช ๐Ÿ‡ง๐Ÿ‡ฟ ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡ฒ ๐Ÿ‡ง๐Ÿ‡น ๐Ÿ‡ง๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฆ ๐Ÿ‡ง๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ท ๐Ÿ‡ฎ๐Ÿ‡ด ๐Ÿ‡ป๐Ÿ‡ฌ ๐Ÿ‡ง๐Ÿ‡ณ ๐Ÿ‡ง๐Ÿ‡ฌ ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡ง๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ป ๐Ÿ‡ฐ๐Ÿ‡ญ ๐Ÿ‡จ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฆ ๐Ÿ‡ฐ๐Ÿ‡พ ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡จ๐Ÿ‡ฑ ๐Ÿ‡จ๐Ÿ‡ณ ๐Ÿ‡จ๐Ÿ‡ฝ ๐Ÿ‡จ๐Ÿ‡จ ๐Ÿ‡จ๐Ÿ‡ด ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฐ ๐Ÿ‡จ๐Ÿ‡ท ๐Ÿ‡ญ๐Ÿ‡ท ๐Ÿ‡จ๐Ÿ‡พ ๐Ÿ‡จ๐Ÿ‡ฟ ๐Ÿ‡จ๐Ÿ‡ฟ ๐Ÿ‡จ๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฐ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ฉ๐Ÿ‡ฒ ๐Ÿ‡ฉ๐Ÿ‡ด EA ๐Ÿ‡ช๐Ÿ‡จ ๐Ÿ‡ช๐Ÿ‡ฌ ๐Ÿ‡ธ๐Ÿ‡ป ๐Ÿ‡ฌ๐Ÿ‡ถ ๐Ÿ‡ช๐Ÿ‡ท ๐Ÿ‡ช๐Ÿ‡ช ๐Ÿ‡ธ๐Ÿ‡ฟ ๐Ÿ‡ช๐Ÿ‡น ET ๐Ÿ‡ซ๐Ÿ‡ฐ ๐Ÿ‡ซ๐Ÿ‡ด ๐Ÿ‡ซ๐Ÿ‡ฏ ๐Ÿ‡ซ๐Ÿ‡ฎ ๐Ÿ‡ซ๐Ÿ‡ท ๐Ÿ‡ฌ๐Ÿ‡ซ ๐Ÿ‡ต๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ซ ๐Ÿ‡ฌ๐Ÿ‡ฆ ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ต๐Ÿ‡ธ ๐Ÿ‡ฌ๐Ÿ‡ช ๐Ÿ‡ฉ๐Ÿ‡ช ๐Ÿ‡ฌ๐Ÿ‡ญ ๐Ÿ‡ฌ๐Ÿ‡ฎ ๐Ÿ‡ฌ๐Ÿ‡ท ๐Ÿ‡ฌ๐Ÿ‡ฑ ๐Ÿ‡ฌ๐Ÿ‡ฉ ๐Ÿ‡ฌ๐Ÿ‡ต ๐Ÿ‡ฌ๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ฌ๐Ÿ‡พ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ญ๐Ÿ‡ฒ ๐Ÿ‡ญ๐Ÿ‡ณ ๐Ÿ‡ญ๐Ÿ‡ฐ ๐Ÿ‡ญ๐Ÿ‡บ ๐Ÿ‡ฎ๐Ÿ‡ธ ๐Ÿ‡ฎ๐Ÿ‡ณ ๐Ÿ‡ฎ๐Ÿ‡ฉ IN ๐Ÿ‡ฎ๐Ÿ‡ท ๐Ÿ‡ฎ๐Ÿ‡ถ ๐Ÿ‡ฎ๐Ÿ‡ช ๐Ÿ‡ฎ๐Ÿ‡ฑ IS ๐Ÿ‡ฎ๐Ÿ‡น ๐Ÿ‡ฏ๐Ÿ‡ฒ ๐Ÿ‡ฏ๐Ÿ‡ต ๐Ÿ‡ฏ๐Ÿ‡ด ๐Ÿ‡ฐ๐Ÿ‡ฟ ๐Ÿ‡ฐ๐Ÿ‡ช ๐Ÿ‡ฐ๐Ÿ‡ฎ KO ๐Ÿ‡ฐ๐Ÿ‡ผ ๐Ÿ‡ฐ๐Ÿ‡ฌ ๐Ÿ‡ฑ๐Ÿ‡ฆ ๐Ÿ‡ฑ๐Ÿ‡ป ๐Ÿ‡ฑ๐Ÿ‡ง ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฑ๐Ÿ‡พ ๐Ÿ‡ฑ๐Ÿ‡ฎ ๐Ÿ‡ฑ๐Ÿ‡น ๐Ÿ‡ฑ๐Ÿ‡บ ๐Ÿ‡ฒ๐Ÿ‡ด ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡พ ๐Ÿ‡ฒ๐Ÿ‡ป ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡น ๐Ÿ‡ฒ๐Ÿ‡ญ ๐Ÿ‡ฒ๐Ÿ‡ถ ๐Ÿ‡ฒ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡บ ๐Ÿ‡พ๐Ÿ‡น ๐Ÿ‡ฒ๐Ÿ‡ฝ ๐Ÿ‡ซ๐Ÿ‡ฒ ๐Ÿ‡ฒ๐Ÿ‡ฉ ๐Ÿ‡ฒ๐Ÿ‡จ ๐Ÿ‡ฒ๐Ÿ‡ณ ๐Ÿ‡ฒ๐Ÿ‡ช ๐Ÿ‡ฒ๐Ÿ‡ธ ๐Ÿ‡ฒ๐Ÿ‡ฆ ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ฒ๐Ÿ‡ฒ ๐Ÿ‡ณ๐Ÿ‡ฆ ๐Ÿ‡ณ๐Ÿ‡ท ๐Ÿ‡ณ๐Ÿ‡ต ๐Ÿ‡ณ๐Ÿ‡ฑ NE ๐Ÿ‡ณ๐Ÿ‡จ ๐Ÿ‡ณ๐Ÿ‡ฟ ๐Ÿ‡ณ๐Ÿ‡ฎ ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ณ๐Ÿ‡ฌ ๐Ÿ‡ณ๐Ÿ‡บ ๐Ÿ‡ณ๐Ÿ‡ซ ๐Ÿ‡ฒ๐Ÿ‡ฐ ๐Ÿ‡ณ๐Ÿ‡ด ๐Ÿ‡ด๐Ÿ‡ฒ ๐Ÿ‡ต๐Ÿ‡ฐ ๐Ÿ‡ต๐Ÿ‡ผ ๐Ÿ‡ต๐Ÿ‡ฆ ๐Ÿ‡ต๐Ÿ‡ฌ ๐Ÿ‡ต๐Ÿ‡พ ๐Ÿ‡ต๐Ÿ‡ช ๐Ÿ‡ต๐Ÿ‡ญ ๐Ÿ‡ต๐Ÿ‡ณ ๐Ÿ‡ต๐Ÿ‡ฑ ๐Ÿ‡ต๐Ÿ‡น ๐Ÿ‡ต๐Ÿ‡ท ๐Ÿ‡ถ๐Ÿ‡ฆ ๐Ÿ‡จ๐Ÿ‡ฌ ๐Ÿ‡ท๐Ÿ‡ช ๐Ÿ‡ท๐Ÿ‡ด ๐Ÿ‡ท๐Ÿ‡บ ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ธ๐Ÿ‡ญ ๐Ÿ‡ฐ๐Ÿ‡ณ ๐Ÿ‡ฑ๐Ÿ‡จ ๐Ÿ‡ต๐Ÿ‡ฒ ๐Ÿ‡ป๐Ÿ‡จ ๐Ÿ‡ผ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡ฒ ๐Ÿ‡ธ๐Ÿ‡ฆ SA ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ท๐Ÿ‡ธ SE SE ๐Ÿ‡ธ๐Ÿ‡จ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ธ๐Ÿ‡ฌ ๐Ÿ‡ธ๐Ÿ‡ฐ ๐Ÿ‡ธ๐Ÿ‡ฎ ๐Ÿ‡ธ๐Ÿ‡ง ๐Ÿ‡ธ๐Ÿ‡ด ๐Ÿ‡ฟ๐Ÿ‡ฆ ๐Ÿ‡ฐ๐Ÿ‡ท ๐Ÿ‡ธ๐Ÿ‡ธ SO SO ๐Ÿ‡ช๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ฐ ๐Ÿ‡ธ๐Ÿ‡ฉ SU ๐Ÿ‡ธ๐Ÿ‡ท ๐Ÿ‡ธ๐Ÿ‡ฏ ๐Ÿ‡ธ๐Ÿ‡ช ๐Ÿ‡จ๐Ÿ‡ญ ๐Ÿ‡ธ๐Ÿ‡พ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ผ ๐Ÿ‡น๐Ÿ‡ฏ ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ญ ๐Ÿ‡น๐Ÿ‡ฑ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡น๐Ÿ‡ฐ ๐Ÿ‡น๐Ÿ‡ด TR ๐Ÿ‡น๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ณ ๐Ÿ‡น๐Ÿ‡ท ๐Ÿ‡น๐Ÿ‡ฒ ๐Ÿ‡น๐Ÿ‡จ ๐Ÿ‡น๐Ÿ‡ป ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡บ๐Ÿ‡ฆ ๐Ÿ‡ฆ๐Ÿ‡ช ๐Ÿ‡ฌ๐Ÿ‡ง UN ๐Ÿ‡บ๐Ÿ‡พ ๐Ÿ‡บ๐Ÿ‡ฟ ๐Ÿ‡ป๐Ÿ‡บ ๐Ÿ‡ป๐Ÿ‡ฆ ๐Ÿ‡ป๐Ÿ‡ช ๐Ÿ‡ป๐Ÿ‡ณ ๐Ÿ‡ผ๐Ÿ‡ซ ๐Ÿ‡ต๐Ÿ‡ธ ๐Ÿ‡ช๐Ÿ‡ญ ๐Ÿ‡พ๐Ÿ‡ช ๐Ÿ‡ฟ๐Ÿ‡ฒ ๐Ÿ‡ฟ๐Ÿ‡ผ
KR ๐Ÿ‡ฐ๐Ÿ‡ท
MA ๐Ÿ‡ฒ๐Ÿ‡ฆ
OM ๐Ÿ‡ด๐Ÿ‡ฒ
P ๐Ÿ‡จ๐Ÿ‡ท ๐Ÿ‡ฉ๐Ÿ‡ด ๐Ÿ‡ธ๐Ÿ‡ป ๐Ÿ‡ฌ๐Ÿ‡น ๐Ÿ‡ญ๐Ÿ‡ณ ๐Ÿ‡ณ๐Ÿ‡ฎ
PA ๐Ÿ‡ต๐Ÿ‡ฆ
PE ๐Ÿ‡ต๐Ÿ‡ช
S ๐Ÿ‡จ๐Ÿ‡ฆ ๐Ÿ‡ฒ๐Ÿ‡ฝ
SG ๐Ÿ‡ธ๐Ÿ‡ฌ
Column 2 Rate of Duty15.4ยข/kg + 45%
Quota QuantityN/A
Additional DutiesN/A

Overview

This classification covers "Other" compounds containing a phenothiazine ring-system, not further fused, when classified as drugs. It serves as a residual category for drugs of this structural class that do not fall under the specific subcategory of antidepressants, tranquilizers, and other psychotherapeutic agents. Therefore, this code would be utilized for phenothiazine derivatives used in medicinal applications that do not primarily serve a psychotherapeutic function.

To distinguish this category from its sibling, 2934.30.23.00, it is crucial to identify the primary therapeutic or intended use of the phenothiazine-based drug. While the sibling category is exclusively for psychotropic agents, this "Other" classification is for phenothiazine drugs with different pharmacological actions or intended uses within the broader scope of medicinal applications. Examples might include drugs used for antiemetic purposes or other specific therapeutic interventions where the phenothiazine moiety is present but the primary indication is not psychotherapeutic.

As this is a leaf node, there are no further subcategories. Classification under 2934.30.27.00 is final for eligible phenothiazine-based drugs that do not fit into more specific categories. The determination rests on carefully examining the drug's approved indications, pharmacological profile, and intended use as detailed in relevant pharmaceutical documentation.

Stay Updated

Join our newsletter to get all updates of the harmonized Tariff Schedule.